CAR-T Archives

News and Trends 27 Oct 2016

UPDATE: Future of CAR-T shaken by Novartis R&D Shuffle

After a promising kick off, Novartis is raising doubts about the future of its CAR-T program with its decision to dissolve and reintegrate the cell and gene therapy division into its immuno-oncology effort. Yes, you read that correctly: despite exciting progress by Novartis’s CAR-T therapy program, the company is reportedly disbanding the cell and gene therapy […]

October 27, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 29 Sep 2016

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off treatment. But all that glitters is not gold; experts remind us it is important to be critical about the immuno-oncology hype. Immuno-oncology has become all the rage lately, and the hype has led to some major investments, acquisitions, deals and partnerships. It seems […]

September 29, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Aug 2016

How did Cancer Cell Therapy become reality?

Using the body’s own tools to eradicate cancers has been a dream of Medicine for quite some time. How did the field of immuno-oncology evolve into today’s Biotech hype? The near-miraculous results of immuno-oncology cell therapies have dominated news about cancer breakthroughs. Indeed, CAR-T is a game-changer and are at the forefront of the ways Biotech […]

August 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

car t cd19 fda juno therapeutics cerebral edema

News and Trends 18 Jul 2016

UPDATED: Storm on the CAR-T field – 3 patients die in Phase II Study

A CAR-T program in Phase II trials (from Juno Therapeutics) was suspended by the FDA after 3 deaths, which could be treatment-related. How will this impact the field, given that most CAR-T Biotechs share the same target? UPDATE (article originally published on 8/7/2016): the FDA has allowed Juno Therapeutics to resume its CAR-T trial with […]

July 18, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 23 Jun 2016

Cellectis gets paid for a first Milestone, Investors are pleased

After successfully ‘saving’ two babies with terminal-stage acute Leukemia, Cellectis finally treated the first patient in its Phase I trial. A major milestone that could confirm the potential of its lead candidate UCART-19. It’s once again a success for the French biotech company! As it announced on Monday, the first patient has been treated in […]

June 23, 2016 - 2 minutesmins - By Jerome Topsent

cellectis cancer leukemia ucart19 car t cell therapy GOSH baby second biotech

News and Trends 9 May 2016

Universal CAR-T given to Second baby with aggressive Leukemia

Once again, the French biotech Cellectis has hit headlines after having treated a second infant suffering from an aggressive form of Leukemia with their UCART19 therapy. Also based at the famous Great Ormond Street Hospital (GOSH) in London, another child has been treated with the first ever Universal CAR-T cell therapy. The child in question […]

May 9, 2016 - 2 minutesmins - By Dani Bancroft

txcell ospedale san raffaele lupus nephritis car treg

News and Trends 27 Apr 2016

CAR-T for Lupus with French-Italian Partnership

TxCell and Ospedale San Raffaele have partnered up to research a new treatment for Lupus, based on engineered regulatory T-cells (CAR-Treg). TxCell is developing immunotherapies based on the discovery of a type of T-cells that have anti-inflammatory properties – regulatory T lymphocytes (Tregs). Tregs have already yielded two candidates. Osave is currently on phase IIb […]

April 27, 2016 - 2 minutesmins - By Denise Neves Gameiro

xCelligence ols biosciences car t cancer cytotoxicity assay

News and Trends 12 Apr 2016

How CAR-T Cells Kill Cancer: Pictures start Moving

CAR-T is a groundbreaking personalized cancer therapy with tremendous potential to drive the patient’s own immune cells to specifically target and kill cancer cells. Because the development of this therapy is still in the early phase, new tools are needed to provide a quick potency assay to assess the cytotoxicity of the therapeutic T-cells prior […]

April 12, 2016 - 6 minutesmins - By Jerome Topsent

News and Trends 21 Mar 2016

CAR-T Startup Gets €51M from Top&New Investors

Autolus (UK) has secured over €51M in a recent series B round, led by the biggest Biotech VC in Europe – and a new player in life science investment. Autolus is a 1-year-old spin-off of the University College London (UCL) focusing on the development of next-generation CAR-T therapies, addressing current limitations of this ‘wonder therapy‘. […]

March 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

gsk miltenyi biotech gmp cell gene therapy tcr car t

News and Trends 17 Mar 2016

GSK partners to Scale Manufacturing of CAR-T Therapies

Production of CAR-T therapies seems to be one of the biggest challenge of this promising technology. Miltenyi Biotec (Germany) and GSK have entered a new partnership to combine the clinical development of cell and gene therapies with manufacturing expertise. Milteniy is a German company of 1600 employees developing products for biomedical research and cellular therapy. It’s not the first […]

March 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

cancer top 8 biotech immunooncology europe oncology

News and Trends 7 Mar 2016

Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them

With more than 200 types of cancer, the possibility of developing a Universal Cure is in reality, a myth. However, the fight against the World’s Deadliest Cancers is far from being lost… Simply by having a quick look through our articles, we can easily confirm that cancer is one of the World’s main concerns in […]

March 7, 2016 - 2 minutesmins - By Dani Bancroft

DIRK BUSCH TECHNICAL UNIVERSITY MUNICH car t leukemia all

News and Trends 17 Feb 2016

Cancer: World Best Ever CAR-T Results have Just been Disclosed

These are the best results yet for CAR-T, this time from a research group led by Dirk Busch at the Technical University of Munich (Germany). In part backed by Juno Therapeutics, a method to select more potent T-cells and engineer a safety mechanism was announced at the annual meeting of the AAAS in Washington (US). CAR-T therapies are one of the ways […]

February 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

CAR-T

UPDATE: Future of CAR-T shaken by Novartis R&D Shuffle

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

How did Cancer Cell Therapy become reality?

UPDATED: Storm on the CAR-T field – 3 patients die in Phase II Study

Cellectis gets paid for a first Milestone, Investors are pleased

Universal CAR-T given to Second baby with aggressive Leukemia

CAR-T for Lupus with French-Italian Partnership

How CAR-T Cells Kill Cancer: Pictures start Moving

CAR-T Startup Gets €51M from Top&New Investors

GSK partners to Scale Manufacturing of CAR-T Therapies

Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them

Cancer: World Best Ever CAR-T Results have Just been Disclosed

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!